| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 05/07/2026 |
3. Issuer Name and Ticker or Trading Symbol
Odyssey Therapeutics, Inc. [ ODTX ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Series A Convertible Preferred Stock | (1) | (1) | Common Stock | 474,048 | (1) | I | See Note 2(2) |
| Series A-2 Convertible Preferred Stock | (3) | (3) | Common Stock | 139,366 | (3) | I | See Note 2(2) |
| Series B Convertible Preferred Stock | (4) | (4) | Common Stock | 59,692 | (4) | I | See Note 2(2) |
| Series C Convertible Preferred Stock | (5) | (5) | Common Stock | 61,762 | (5) | I | See Note 2(2) |
| Series D Convertible Preferred Stock | (6) | (6) | Common Stock | 683,817 | (6) | I | See Note 2(2) |
| Series D Warrants (Right to Buy) | (7) | (7) | Common Stock | 191,541 | $0.1 | I | See Note 2(2) |
| Series A Convertible Preferred Stock | (1) | (1) | Common Stock | 118,512 | (1) | I | See Note 8(8) |
| Series B Convertible Preferred Stock | (4) | (4) | Common Stock | 255,823 | (4) | I | See Note 8(8) |
| Series B Convertible Preferred Stock | (4) | (4) | Common Stock | 204,658 | (4) | I | See Note 9(9) |
| Series C Convertible Preferred Stock | (5) | (5) | Common Stock | 20,582 | (5) | I | See Note 9(9) |
| Series D Convertible Preferred Stock | (6) | (6) | Common Stock | 166,168 | (6) | I | See Note 9(9) |
| Series D Warrants (Right to Buy) | (7) | (7) | Common Stock | 49,850 | $0.1 | I | See Note 9(9) |
| Series C Convertible Preferred Stock | (5) | (5) | Common Stock | 463,106 | (5) | I | See Note 10(10) |
| Series D Convertible Preferred Stock | (6) | (6) | Common Stock | 273,527 | (6) | I | See Note 10(10) |
| Series D Warrants (Right to Buy) | (7) | (7) | Common Stock | 78,656 | $0.1 | I | See Note 10(10) |
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
|
| Explanation of Responses: |
| 1. The Series A Preferred Stock is convertible into Common Stock on a 1-for-9.7170 basis at any time at the option of the holder. The Series A Preferred Stock will convert immediately prior to the closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration. |
| 2. The securities are directly held by SR One Capital Fund I Aggregator, LP ("SR One Fund I Aggregator"). SR One Capital Partners I, LP ("SR One Partners I") is the sole general partner of SR One Fund I Aggregator, and SR One Capital Management, LLC ("SR One Capital Management") is the sole general partner of SR One Partners I. Simeon George, M.D. is the managing member of SR One Capital Management. Each of SR One Capital Partners I, SR One Capital Management and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein. |
| 3. The Series A-2 Preferred Stock is convertible into Common Stock on a 1-for-9.3268 basis at any time at the option of the holder. The Series A-2 Preferred Stock will convert immediately prior to the closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration. |
| 4. The Series B Preferred Stock is convertible into Common Stock on a 1-for-9.2837 basis at any time at the option of the holder. The Series B Preferred Stock will convert immediately prior to the closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration. |
| 5. The Series C Preferred Stock is convertible into Common Stock on a 1-for-9.7170 basis at any time at the option of the holder. The Series C Preferred Stock will convert immediately prior to the closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration. |
| 6. The Series D Preferred Stock is convertible into Common Stock on a 1-for-9.7170 basis at any time at the option of the holder. The Series D Preferred Stock will convert immediately prior to the closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration. |
| 7. The warrants to purchase shares of Common Stock were immediately exercisable by their terms beginning on June 16, 2025. The Common Stock warrants will be exercised immediately prior to the closing of the Issuer's initial public offering into the number of shares shown in column 3 on a net exercise basis. |
| 8. The securities are directly held by SR One Co-Invest IV, LLC ("SR One Co-Invest IV"). SR One Co-Invest IV Manager, LLC ("SR One Co-Invest Manager") is the managing member of SR One-Co-Invest IV, and SR One Capital Management is the managing member of SR One Co-Invest Manager. Simeon George, M.D. is the managing member of SR One Capital Management. Each of SR One Co-Invest Manager, SR One Capital Management and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein. |
| 9. The securities are directly held by SR One Co-Invest IV-A, LLC ("SR One Co-Invest IV-A"). SR One Co-Invest IV Manager is the managing member of SR One-Co-Invest IV-A, and SR One Capital Management is the managing member of SR One Co-Invest Manager. Simeon George, M.D. is the managing member of SR One Capital Management. Each of SR One Co-Invest Manager, SR One Capital Management and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein. |
| 10. The reported securities are held directly by AMZL, LP ("AMZL"). SR One Capital SMA Partners, LP ("SR One SMA Partners") is the general partner of AMZL, and SR One Capital Management is the general partner of SR One SMA Partners. Simeon George, M.D. is the managing member of SR One Capital Management. Each of SR One SMA Partners, SR One Capital Management and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein. |
| /s/ Sasha Keough, attorney-in-fact for SR One Capital Management, LLC | 05/07/2026 | |
| /s/ Sasha Keough, attorney-in-fact for Simeon George | 05/07/2026 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||